199 related articles for article (PubMed ID: 23054462)
1. Dichotomous effects of exposure to bivalirudin in patients undergoing percutaneous coronary intervention on protease-activated receptor-mediated platelet activation.
Holinstat M; Colowick NE; Hudson WJ; Blakemore D; Chen Q; Hamm HE; Cleator JH
J Thromb Thrombolysis; 2013 Feb; 35(2):209-22. PubMed ID: 23054462
[TBL] [Abstract][Full Text] [Related]
2. Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention.
Kimmelstiel C; Zhang P; Kapur NK; Weintraub A; Krishnamurthy B; Castaneda V; Covic L; Kuliopulos A
Circ Cardiovasc Interv; 2011 Apr; 4(2):171-9. PubMed ID: 21364148
[TBL] [Abstract][Full Text] [Related]
3. Enhanced potency of prasugrel on protease-activated receptors following bivalirudin treatment for PCI as compared to clopidogrel.
Kimmelstiel C; Stevenson R; Nguyen N; Van Doren L; Zhang P; Perkins J; Kapur NK; Weintraub A; Castaneda V; Kuliopulos A; Covic L
Thromb Res; 2019 May; 177():59-69. PubMed ID: 30851630
[TBL] [Abstract][Full Text] [Related]
4. [Role of adenosine diphosphate in the course of thrombin signal transmission].
Han Y; Lu XX; Wang ZY; Dai L; Shen WH; Wu DP; Ruan CG
Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(46):3299-301. PubMed ID: 17313817
[TBL] [Abstract][Full Text] [Related]
5. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis.
Leger AJ; Jacques SL; Badar J; Kaneider NC; Derian CK; Andrade-Gordon P; Covic L; Kuliopulos A
Circulation; 2006 Mar; 113(9):1244-54. PubMed ID: 16505172
[TBL] [Abstract][Full Text] [Related]
6. Protease-activated receptors differentially regulate human platelet activation through a phosphatidic acid-dependent pathway.
Holinstat M; Voss B; Bilodeau ML; Hamm HE
Mol Pharmacol; 2007 Mar; 71(3):686-94. PubMed ID: 17151288
[TBL] [Abstract][Full Text] [Related]
7. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
Bilodeau ML; Hamm HE
J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
[TBL] [Abstract][Full Text] [Related]
8. Platelet protease-activated receptor (PAR)4, but not PAR1, associated with neutral sphingomyelinase responsible for thrombin-stimulated ceramide-NF-κB signaling in human platelets.
Chen WF; Lee JJ; Chang CC; Lin KH; Wang SH; Sheu JR
Haematologica; 2013 May; 98(5):793-801. PubMed ID: 23065519
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation.
Wu CC; Teng CM
Eur J Pharmacol; 2006 Sep; 546(1-3):142-7. PubMed ID: 16890935
[TBL] [Abstract][Full Text] [Related]
10. Bivalirudin inhibits periprocedural platelet function and tissue factor expression of human smooth muscle cells.
Pepke W; Eisenreich A; Jaster M; Ayral Y; Bobbert P; Mayer A; Schultheiss HP; Rauch U
Cardiovasc Ther; 2013 Apr; 31(2):115-23. PubMed ID: 22212466
[TBL] [Abstract][Full Text] [Related]
11. PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y12 receptor activation.
Holinstat M; Voss B; Bilodeau ML; McLaughlin JN; Cleator J; Hamm HE
J Biol Chem; 2006 Sep; 281(36):26665-74. PubMed ID: 16837456
[TBL] [Abstract][Full Text] [Related]
12. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.
Judge HM; Jennings LK; Moliterno DJ; Hord E; Ecob R; Tricoci P; Rorick T; Kotha J; Storey RF
Platelets; 2015; 26(3):236-42. PubMed ID: 24750101
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood.
French SL; Arthur JF; Lee H; Nesbitt WS; Andrews RK; Gardiner EE; Hamilton JR
J Thromb Haemost; 2016 Aug; 14(8):1642-54. PubMed ID: 26878340
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide.
Kleiman NS; Klem J; Fernandes LS; Rubin H; Challa S; Solomon S; Maresh K; Arora U; Klem E; Buergler J; Mathew S; Browning A; DeLao T
Am Heart J; 2002 Apr; 143(4):585-93. PubMed ID: 11923794
[TBL] [Abstract][Full Text] [Related]
15. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin.
Anand SX; Kim MC; Kamran M; Sharma SK; Kini AS; Fareed J; Hoppensteadt DA; Carbon F; Cavusoglu E; Varon D; Viles-Gonzalez JF; Badimon JJ; Marmur JD
Am J Cardiol; 2007 Aug; 100(3):417-24. PubMed ID: 17659921
[TBL] [Abstract][Full Text] [Related]
16. Protease-activated receptor-4 (PAR4) variant influences on platelet reactivity induced by PAR4-activating peptide through altered Ca
Morikawa Y; Kato H; Kashiwagi H; Nishiura N; Akuta K; Honda S; Kanakura Y; Tomiyama Y
Thromb Res; 2018 Feb; 162():44-52. PubMed ID: 29289806
[TBL] [Abstract][Full Text] [Related]
17. Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin and bivalirudin.
Eslam RB; Reiter N; Kaider A; Eichinger S; Lang IM; Panzer S
Eur Heart J; 2009 Aug; 30(15):1831-6. PubMed ID: 19468011
[TBL] [Abstract][Full Text] [Related]
18. Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions.
Hosokawa K; Ohnishi T; Miura N; Sameshima H; Koide T; Tanaka KA; Maruyama I
Thromb Res; 2014 Jan; 133(1):66-72. PubMed ID: 24268424
[TBL] [Abstract][Full Text] [Related]
19. The ATP-gated P2X1 receptor plays a pivotal role in activation of aspirin-treated platelets by thrombin and epinephrine.
Grenegård M; Vretenbrant-Oberg K; Nylander M; Désilets S; Lindström EG; Larsson A; Ramström I; Ramström S; Lindahl TL
J Biol Chem; 2008 Jul; 283(27):18493-504. PubMed ID: 18480058
[TBL] [Abstract][Full Text] [Related]
20. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets.
Covic L; Gresser AL; Kuliopulos A
Biochemistry; 2000 May; 39(18):5458-67. PubMed ID: 10820018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
